Although genetic deletion of tumor-intrinsic COX2 resulted in a drastic repolarization of the TME, increased tumor control, and sensitization to ICB, we next sought to assess whether pharmacologic blockade of COX2 could have similar effects. The gene discussed is PTGS2; the disease is neoplasm.